

Special Issue

Advances in Therapy of Acute Myeloid Leukemia

Message from the Guest Editor

In recent years, new targeted therapies have developed in AML. These agents target various cellular processes: signaling pathways, DNA methylation, or chromatin remodeling. The new therapies include FLT3 inhibitors, IDH inhibitors, and Bcl-2 inhibitors. Each of these new therapies has different pharmacological profiles, adverse effects, and levels of effectiveness. A solid knowledge of the molecular basis of AML allows for the conscious application of new therapies. However, there is a large group of AML patients for whom molecular and genetic factors are unknown. Relapsed patients are particularly classified as being at significant risk. It is thus necessary to search for new molecular, genetic, and immunological factors that can play a prognostic role and become the target of new AML therapies in the future.

This Special Issue will be dedicated to new prognostic factors, and new therapies used in AML. Suitable topics include, but are not limited to: acute myeloid leukemia; new prognostic factors in acute myeloid leukemia; potential targeted therapies; pathogenesis of acute myeloid leukemia.

Guest Editor

Prof. Dr. Justyna Rybka

Clinic and Department of Hematology, Cellular Therapies and Internal Medicine, Wrocław Medical University, Pasteur 4 Street, 50-367 Wrocław, Poland

Deadline for manuscript submissions

closed (15 March 2024)



International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/127078

*International Journal of
Molecular Sciences*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
ijms@mdpi.com

[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)





International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)



About the Journal

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Editor-in-Chief

Prof. Dr. José L. Quiles
Department of Physiology, Institute of Nutrition and Food Technology
"Jose Mataix", Biomedical Research Center, University of Granada,
Avda. Conocimiento s/n, 18100 Armilla, Granada, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)